Summary of Innate Pharma (IPHA) Q2 2026 Earnings Call

1Key Financial Results and Metrics

As of June 30, 2026, Innate Pharma reported cash equivalents and financial assets of €21.4 million.

The company received a $75 million upfront payment from Sobi, equivalent to €65 million, and completed a €30 million equity financing, netting approximately €28 million.

These funds are expected to extend the company's cash runway through the end of Q1 2028.

2Strategic Updates and Business Highlights

Lacutamab: A strategic partnership with Sobi was finalized, allowing for the advancement of lacutamab in T cell lymphoma. The TELLOMAK-3 Phase 3 study has been initiated, with the first patient expected in Q1 2027. An accelerated approval filing for Sezary Syndrome is planned for the second half of 2027.

IPH4.5 Thousand: The Phase 1 dose escalation and cohort enrichment for IPH4.5 thousand have been completed, showing preliminary antitumor activity and a favorable safety profile. Initial data will be presented at the EORTC-NCI-AACR meeting on November 18, 2026.

Monalizumab: Enrollment in the PACIFIC-9 Phase 3 study has been completed, with results expected in the second half of 2026. This study involves 1,050 patients and compares monalizumab with other treatments for non-small cell lung cancer.

3Forward Guidance and Outlook

Innate Pharma anticipates several key catalysts in the second half of 2026, including:

Initial Phase 1 data for IPH4.5 thousand.

Phase 3 readout for monalizumab.

Progress on the TELLOMAK-3 study for lacutamab.

The company is well-positioned financially to advance its clinical programs, particularly for IPH4.5 thousand.

4Bad News, Challenges, or Points of Concern

There are inherent risks associated with clinical trials, including the potential for adverse outcomes in ongoing studies.

The competitive landscape for ADCs and immunotherapies remains intense, with the need to demonstrate clear differentiation and efficacy against existing therapies.

The company must navigate regulatory hurdles and market acceptance, particularly for new therapies like lacutamab and IPH4.5 thousand.

5Notable Q&A Insights

Safety Concerns: In response to questions about potential hematological toxicities associated with IPH4.5 thousand, the company highlighted the stability of their linker design, which aims to minimize systemic toxicity.

Off-label Use: There is an expectation for off-label use of lacutamab in Sezary Syndrome, particularly after its anticipated NCCN guideline listing.

Pricing Strategy: Innate Pharma has conducted pricing research indicating they could price lacutamab between $500,000 and $650,000 per patient annually, potentially at a premium due to its targeted indications.

Future Communications: The company plans to issue press releases regarding the PACIFIC-9 results alongside AstraZeneca, ensuring transparency and communication with stakeholders. Overall, Innate Pharma is positioned for significant developments in the coming months, with a solid financial foundation and promising clinical data on the horizon. However, the company must remain vigilant regarding competitive pressures and regulatory challenges.